GlassScriptPhysician profile
Keith S Gersin
NPI 1679504245
$80,491.79
in general payments reported to CMS, 2019-2025
14 companies · $8,381 in 2025
The $8,381 reported for 2025 was more than what 94% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,597 · 2021: $6,033 · 2022: $1,273 · 2023: $18K · 2024: $26K · 2025: $8,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $6,795 · Food and Beverage: $4,842 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,012.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,600.00 |
| Travel and Lodging | $6,795.06 |
| Food and Beverage | $4,841.69 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $39,722.76 | 2019-2025 | Gore Bio-A Tissue Reinforcement, Gore Enform Preperitoneal Biomaterial, Gore Synecor Biomaterial |
| Teleflex LLC | $22,256.45 | 2023-2025 | Titan Sgs, Titan Sgs Bailout Chuck, Titan Sgs Standard Gastric Stapler |
| Pacira Pharmaceuticals Incorporated | $6,148.81 | 2024 | Exparel |
| Davol INC. | $3,203.53 | 2021 | |
| Intuitive Surgical, INC. | $2,799.43 | 2024-2025 | |
| Ethicon US, LLC | $2,316.18 | 2019-2025 | Echelon; Endopath, Enseal X1, Echelon Endopath |
| Novo Nordisk INC | $2,292.50 | 2025 | |
| Standard Bariatrics, INC. | $1,127.44 | 2021-2022 | |
| Covidien LP | $304.24 | 2019 | |
| Apollo Endosurgery US INC | $134.84 | 2022 | |
| Medical Device Business Services, INC. | $119.10 | 2024 | Echelon Flex |
| Medtronic, INC. | $66.51 | 2022-2024 | Ligasure |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$240,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Gersin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.